3-(3-bromopropyl)-1H-indole-5-carbonitrile | 843654-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(3-bromopropyl)-1H-indole-5-carbonitrile
• CAS: 843654-50-2
• 化学式: C₁₂H₁₁BrN₂
• 分子量: 263.137
• InChiKey: GZEJFLFQENGELM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-bromopropyl)-1H-indole-5-carbonitrile 、 N-cyclohexyl-N-phenyl-2-(piperazin-1-yl)acetamide 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Higher-Affinity Agonists of 5-HT_1AR Discovered through Tuning the Binding-Site Flexibility

  摘要：

  Discovery of high-affinity and high-selectivity agonists of 5-HT1AR. has become very attractive due to their potential therapeutic effects on multiple 5-HT1AR-related psychological and neurological problems. On the basis of our previously designed lead compound FW01 (K-i = 51.9 nM, denoted as 9a in the present study), we performed large-scale molecular dynamics simulations and molecular docking operations on 5-HT1AR-9a binding. We found the flip-packing events for the headgroup of 9a, and we also found that its tail group could bind flexibly at the agornst-binding site of 5-HT1AR. By finely tuning the flip-packing phenomenon of the 9a headgroup and tuning the binding flexibility of 9a tail group, we virtually designed a series of new 9a derivatives through molecular docking operations and first-principles calculations and predicted that these newly designed 9a derivatives should be higher-affinity agonists of 5-HT1AR. The computational predictions on the new 9a derivatives have been confirmed by our wet-experimental studies as chemical synthesis, binding affinity assays, and agonistic-function assays. The consistency between our computational design and wet-experimental measurements has led to our discovery of higher-affinity agonists of 5-HT1AR, with,similar to 50-fold increase in receptor-binding affinity and similar to 25-fold improvements in agonistic function. In addition, our newly designed 5-HT1AR agonists showed very high selectivity of 5-HT1AR over subtype 5-HT2AR and also over three subtypes of dopamine receptors (D-1, D-2, and D-3).

  DOI：

  10.1021/acs.jcim.5b00164
• 作为产物：
  描述：

  对溴苯肼 在 四溴化碳 、 N,N-二甲基乙酰胺 、 硫酸 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(3-bromopropyl)-1H-indole-5-carbonitrile
  参考文献：
  名称：

  Higher-Affinity Agonists of 5-HT_1AR Discovered through Tuning the Binding-Site Flexibility

  摘要：

  Discovery of high-affinity and high-selectivity agonists of 5-HT1AR. has become very attractive due to their potential therapeutic effects on multiple 5-HT1AR-related psychological and neurological problems. On the basis of our previously designed lead compound FW01 (K-i = 51.9 nM, denoted as 9a in the present study), we performed large-scale molecular dynamics simulations and molecular docking operations on 5-HT1AR-9a binding. We found the flip-packing events for the headgroup of 9a, and we also found that its tail group could bind flexibly at the agornst-binding site of 5-HT1AR. By finely tuning the flip-packing phenomenon of the 9a headgroup and tuning the binding flexibility of 9a tail group, we virtually designed a series of new 9a derivatives through molecular docking operations and first-principles calculations and predicted that these newly designed 9a derivatives should be higher-affinity agonists of 5-HT1AR. The computational predictions on the new 9a derivatives have been confirmed by our wet-experimental studies as chemical synthesis, binding affinity assays, and agonistic-function assays. The consistency between our computational design and wet-experimental measurements has led to our discovery of higher-affinity agonists of 5-HT1AR, with,similar to 50-fold increase in receptor-binding affinity and similar to 25-fold improvements in agonistic function. In addition, our newly designed 5-HT1AR agonists showed very high selectivity of 5-HT1AR over subtype 5-HT2AR and also over three subtypes of dopamine receptors (D-1, D-2, and D-3).

  DOI：

  10.1021/acs.jcim.5b00164

文献信息

• [EN] 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES<br/>[FR] DERIVES 3-AMINO CHOMANE ET 2-AMINO TETRALINE
  申请人：WYETH CORP

  公开号：WO2005012291A1

  公开（公告）日：2005-02-10

  3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

  揭示了3-氨基色苷和2-氨基四氢萘衍生物以及含有这些化合物的组合物。还揭示了在治疗血清素失调症，如抑郁症和焦虑症中使用3-氨基色苷和2-氨基四氢萘化合物以及含有这些化合物的组合物的方法。
• Design, Synthesis, and Structure–Activity Relationship Studies of Novel Indolyalkylpiperazine Derivatives as Selective 5-HT_1A Receptor Agonists
  作者：Wenli Wang、Lan Zheng、Wei Li、Chen Zhu、Weiqing Peng、Bing Han、Wei Fu

  DOI：10.1021/acs.jcim.9b00926

  日期：2020.1.27

  5-HT1A receptor (5-HT1AR) agonists have been implicated in the treatment of a variety of central nervous system (CNS) diseases such as depression and anxiety, et al. Based on our previously found compound FW01 (Ki = 51 ± 16 nM) obtained by virtual screening, a series of FW01 derivatives were designed and synthesized by the modification of the amide tail group as well as indole headgroup of FW01. SAR

  5-HT1A受体（5-HT1AR）激动剂已涉及多种中枢神经系统（CNS）疾病的治疗，例如抑郁症和焦虑症等。基于我们先前发现的通过虚拟筛选获得的化合物FW01（Ki = 51±16 nM），通过修饰FW01的酰胺尾基和吲哚基团设计并合成了一系列FW01衍生物。SAR探索发现，酰胺尾基和吲哚基团在确定对多巴胺和5-羟色胺受体亚型的结合亲和力和选择性中起着关键作用。在所有测试的化合物中，9_24的Ki值为5±0.6 nM，对5-HT1AR的选择性很好。[35S]GTPγS分析显示9_24是对5-HT1AR的完全激动剂，EC50值为0.059 nM，显示为266.2和146。对5-HT2A和D3的选择性是4倍。用5-HT1AR-9_24进行了分子动力学模拟和分子对接研究，以揭示其高活性和选择性的机理。最后，提出了5-HT1AR的逐步9_24诱导信号转导机制。
• 3-Amino chroman and 2-amino tetralin derivatives
  申请人：Hatzenbuhler Theriault Nicole

  公开号：US20050032873A1

  公开（公告）日：2005-02-10

  3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

  本文披露了3-氨基色满和2-氨基四氢萘衍生物及含有这些化合物的组合物。还披露了使用3-氨基色满和2-氨基四氢萘化合物及含有这些化合物的组合物治疗血清素失调症，如抑郁和焦虑的方法。
• AChE/SERT双靶点抑制剂及其制备方法和用途
  申请人：珠海市藤栢医药有限公司

  公开号：CN115974839A

  公开（公告）日：2023-04-18

  本发明公开了AChE/SERT双靶点抑制剂及其制备方法和用途，并具体公开了如式I所示的化合物、其互变异构体、其立体异构体，或前述任一者的药学上可接受的盐，或前述任一者的溶剂化物。本发明化合物同时具有乙酰胆碱酯酶抑制活性和五羟色胺转运体抑制活性，具有良好的体外和体内血脑屏障通透性，用于治疗阿尔茨海默病、抑郁症、阿尔茨海默病和抑郁症共患病，避免联合用药产生的有害的药物相互作用、降低患者的服药难度和身体负担。
• Advances toward New Antidepressants with Dual Serotonin Transporter and 5-HT_1A Receptor Affinity within a Class of 3-Aminochroman Derivatives. Part 2
  作者：Nicole T. Hatzenbuhler、Reinhardt Baudy、Deborah A. Evrard、Amedeo Failli、Boyd L. Harrison、Steven Lenicek、Richard E. Mewshaw、Annmarie Saab、Uresh Shah、Jean Sze、Minsheng Zhang、Dahui Zhou、Michael Chlenov、Michael Kagan、Jeannette Golembieski、Geoffrey Hornby、Margaret Lai、Deborah L. Smith、Kelly M. Sullivan、Lee E. Schechter、Terrance H. Andree

  DOI：10.1021/jm8007097

  日期：2008.11.13

  Novel compounds combining a 5-HT1A moiety (3-aminochroman scaffold) and a 5-HT transporter (indole analogues) linked through,a common basic nitrogen via an alkyl chain attached at the 1- or 3-position of the indole were evaluated for dual affinity at both the 5-HT reuptake site and the 5-HT1A receptor. Compounds of most interest were found to have a 5-carbamoyl-8-fluoro-3-amino-3,4-dihydro-2H-1-benzopyran linked to a 3-alkylindole (straight chain), more specifically substituted with a 5-fluoro ((R)-(-)-35c), 5-cyano ((-)-52a), or 5,7-difluoro ((-)-52g). Several factors contributed to 5-HT1A affinity, serotonin rat transporter affinity, and functional antagonism in vitro. Although most of our analogues showed good to excellent affinities at both targets, specific features such as cyclobutyl substitution on the basic nitrogen and stereochemistry at the 3-position of the chroman moiety seemed necessary for antagonism at the 5-HT1A receptor. Branched linkers seemed to impart antagonism even as racemates, however, potency of these analogues in the functional assay was not desirable enough to further pursue these compounds.